Systemic Bio Wins the SLAS 2025 Innovation Award
Systemic Bio, a 3D Systems (NYSE: DDD) company, has won the prestigious SLAS 2025 Innovation Award for its groundbreaking technological advancements in laboratory science. The award recognizes the company's proprietary h-VIOS™ platform, which accelerates drug discovery using bioprinted human tissues.
The company's winning presentation demonstrated the platform's ability to evaluate antibody-drug conjugates (ADCs) safety, identifying risks typically only discovered during clinical trials. Operating from Houston, Texas, Systemic Bio maintains an ISO 7 clean room and Quality Management System, enabling the production of thousands of tissue models.
CEO Taci Pereira emphasized the award's significance as validation of their platform's scientific value. The company continues collaborating with leading pharmaceutical companies to enhance preclinical drug testing and reduce late-stage failures through their innovative technology.
Systemic Bio, una società di 3D Systems (NYSE: DDD), ha ricevuto il prestigioso SLAS 2025 Innovation Award per i suoi straordinari progressi tecnologici nella scienza di laboratorio. Questo premio riconosce la piattaforma proprietaria h-VIOS™ dell'azienda, che accelera la scoperta di farmaci utilizzando tessuti umani biostampati.
La presentazione vincente dell'azienda ha dimostrato la capacità della piattaforma di valutare la sicurezza dei coniugati anticorpo-farmaco (ADC), identificando rischi che di solito vengono scoperti solo durante le sperimentazioni cliniche. Operando da Houston, Texas, Systemic Bio mantiene una camera bianca ISO 7 e un sistema di gestione della qualità, che consente la produzione di migliaia di modelli tissutali.
Il CEO Taci Pereira ha sottolineato l'importanza del premio come validazione del valore scientifico della loro piattaforma. L'azienda continua a collaborare con importanti compagnie farmaceutiche per migliorare il test preclinico dei farmaci e ridurre i fallimenti nelle fasi avanzate attraverso la loro tecnologia innovativa.
Systemic Bio, una compañía de 3D Systems (NYSE: DDD), ha ganado el prestigioso SLAS 2025 Innovation Award por sus innovadores avances tecnológicos en la ciencia de laboratorio. Este premio reconoce la plataforma propietaria h-VIOS™ de la empresa, que acelera el descubrimiento de medicamentos utilizando tejidos humanos bioprintados.
La presentación ganadora de la compañía demostró la capacidad de la plataforma para evaluar la seguridad de los conjugados anticuerpo-fármaco (ADC), identificando riesgos que normalmente solo se descubren durante los ensayos clínicos. Con sede en Houston, Texas, Systemic Bio mantiene una sala limpia ISO 7 y un sistema de gestión de calidad, lo que permite la producción de miles de modelos de tejido.
El CEO Taci Pereira enfatizó la importancia del premio como una validación del valor científico de su plataforma. La empresa sigue colaborando con importantes compañías farmacéuticas para mejorar las pruebas de medicamentos preclínicos y reducir los fracasos en las etapas avanzadas mediante su tecnología innovadora.
Systemic Bio는 3D Systems (NYSE: DDD) 소속 회사로, 실험실 과학 분야에서의 혁신적인 기술 발전으로 SLAS 2025 Innovation Award를 수상했습니다. 이 상은 생체 프린팅된 인체 조직을 이용해 약물 발견을 가속화하는 회사의 독자적 플랫폼인 h-VIOS™를 인정합니다.
회사의 수상 발표에서는 플랫폼이 항체-약물 접합체 (ADC)의 안전성을 평가하는 능력을 보여주었으며, 이는 임상 시험에서만 발견되는 위험 요소를 식별합니다. 텍사스주 휴스턴에 본사를 둔 Systemic Bio는 ISO 7 청정실과 품질 관리 시스템을 유지하고 있어 수천 개의 조직 모델을 생산할 수 있습니다.
CEO Taci Pereira는 이 상이 그들의 플랫폼 과학 가치의 검증이라는 점에서 중요하다고 강조했습니다. 이 회사는 혁신적인 기술을 통해 임상 이전의 약물 시험을 향상시키고 후기 단계의 실패를 줄이기 위해 주요 제약 회사들과 계속 협력하고 있습니다.
Systemic Bio, une entreprise de 3D Systems (NYSE: DDD), a remporté le prestigieux SLAS 2025 Innovation Award pour ses avancées technologiques révolutionnaires dans le domaine des sciences de laboratoire. Ce prix reconnaît la plateforme propriétaire h-VIOS™ de l'entreprise, qui accélère la découverte de médicaments en utilisant des tissus humains bioprintés.
La présentation gagnante de l'entreprise a démontré la capacité de la plateforme à évaluer la sécurité des conjugués anticorps-médicaments (ADC), identifiant des risques habituellement découverts uniquement lors des essais cliniques. Basée à Houston, Texas, Systemic Bio maintient une salle blanche ISO 7 et un système de gestion de la qualité, permettant la production de milliers de modèles tissulaires.
Le PDG Taci Pereira a souligné l'importance de ce prix comme validation de la valeur scientifique de leur plateforme. L'entreprise continue de collaborer avec des entreprises pharmaceutiques de premier plan pour améliorer les tests de médicaments précliniques et réduire les échecs en fin de phase grâce à leur technologie innovante.
Systemic Bio, ein Unternehmen von 3D Systems (NYSE: DDD), hat den prestigeträchtigen SLAS 2025 Innovation Award für seine bahnbrechenden technologischen Fortschritte in der Laborwissenschaft gewonnen. Der Preis würdigt die proprietäre h-VIOS™-Plattform des Unternehmens, die die Medikamentenentdeckung durch bioprinted menschliche Gewebe beschleunigt.
Die preisgekrönte Präsentation des Unternehmens demonstrierte die Fähigkeit der Plattform, die Sicherheit von Antikörper-Arzneimittel-Konjugaten (ADCs) zu bewerten und Risiken zu identifizieren, die normalerweise nur während klinischer Studien entdeckt werden. Mit Sitz in Houston, Texas, betreibt Systemic Bio einen ISO 7-Reinraum und ein Qualitätsmanagementsystem, die die Produktion von Tausenden von Gewebemodellen ermöglichen.
CEO Taci Pereira betonte die Bedeutung des Preises als Bestätigung des wissenschaftlichen Wertes ihrer Plattform. Das Unternehmen arbeitet weiterhin mit führenden Pharmakonzernen zusammen, um die präklinische Arzneimittelprüfung zu verbessern und spätere Misserfolge durch ihre innovative Technologie zu reduzieren.
- None.
- None.
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Systemic Bio™, a 3D Systems company (NYSE: DDD), has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to drive innovation in laboratory science and automation. The competition featured cutting-edge developments led by distinguished experts from top institutions worldwide.
The award highlights Systemic Bio’s proprietary h-VIOS™ platform, designed to accelerate drug discovery and development using bioprinted human tissues. The Company’s presentation focused on the application of its platform to evaluate the safety of antibody-drug conjugates (ADCs). The technology enables early identification of safety concerns, capturing risks that historically have only been discovered during clinical trials, even after non-human primate studies failed to flag such issues.
“I couldn’t be prouder of our team for winning this award,” said Taci Pereira, CEO of Systemic Bio. “This recognition is a testament to our relentless focus on demonstrating the scientific and translational value of our platform. We remain committed to expanding our capabilities and accelerating adoption to improve drug discovery and development.”
Operating from Houston, Texas, Systemic Bio has the capability to produce thousands of tissue models under an ISO 7 clean room and a Quality Management System (QMS). These models support the Company’s ongoing collaborations with leading pharmaceutical companies to improve preclinical drug testing and reduce late-stage failures.
The SLAS Innovation Award is presented annually at the SLAS International Conference and Exhibition, recognizing the most forward-thinking technological advancements in the field. More information on Systemic Bio’s work can be found at www.systemic.bio.
Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Systemic Bio or 3D Systems, as applicable, to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the beliefs and expectations of Systemic Bio or 3D Systems as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the applicable company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in 3D Systems’ periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. Neither Systemic Bio nor 3D Systems undertakes any obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.
About Systemic Bio
Systemic Bio is a biotech company focused on accelerating drug discovery and development with human-relevant data from its proprietary platform of bioprinted vascularized organ models. Founded in 2022 as a wholly-owned company of 3D Systems, Systemic Bio leverages 3D Systems’ breakthrough, production-level bioprinting technology to create extremely precise healthy and diseased tissues using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities, and then perfused with drugs to study the effects on healthy or diseased tissue at the earliest stages of pharmaceutical drug development. These systems are multimodal and can be used to generate large datasets leveraged with machine learning to generate human-relevant therapeutic insights. More information on the company is available at www.systemic.bio.
About 3D Systems
More than 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials, and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace & defense, automotive, and durable goods. More information on the company is available at www.3dsystems.com.
Investor Contact: investor.relations@3dsystems.com
Media Contact: press@systemic.bio
FAQ
What technology won Systemic Bio (DDD) the SLAS 2025 Innovation Award?
How does Systemic Bio's h-VIOS platform improve drug safety testing?
What is Systemic Bio's (DDD) production capacity for tissue models?
How is Systemic Bio (DDD) collaborating with pharmaceutical companies?
What is the significance of the SLAS 2025 Innovation Award for Systemic Bio (DDD)?
